Syndecan 1 as Biomarker for Inflammation

Helios Albert-Schweitzer-Klinik Northeim

Status: Unknown

Conditions: Colitis

Study type: Observational

Funder types: Other

Identifiers

NCT02333526

Syndecan-NOM

Details and patient eligibility

About

The aim of the study is to evaluate the soluble biomarker syndecan-1 (sSdc1) taken from venous blood of patients with infectious intestinal diseases such as Clostridium difficile-associated colitis, bacterial colitis, Norovirus enteritis and Crohn´s disease or ulcerative colitis. The level of sSdc1 will be compared with disease activity in patients with active inflammation and with disease in remission. Secondary objectives were the assessment of correlation of the above-mentioned factors with the CRP value. Subjects will be volunteers. Blood will be taken as part of the routine clinical work-up after the written agreement blood and sSdc1-level will be assessed using a human-specific sSdc1 ELISA assay. In addition, the subjects are asked to answer a short questionnaire. The study is designed as a prospective, comparative cohort study.

Enrollment: 44 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subject with at least 18 years of age
• able to give informed consent
• healthy volunteer or inflammatory bowel condition (inflammatory bowel disease, infectious colitis)

Exclusion criteria

• not able to give informed consent